deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT05025787

A Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Knee Osteoarthritis Pain.

EN20-01: A 24 Week Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Moderate to Severe Knee Osteoarthritis Pain.

Sponsor: Maurizio Fava, MD

Updated 18 times since 2021 Last updated: Nov 13, 2025 Started: Oct 25, 2021 Primary completion: Jun 11, 2024 Completion: Jun 11, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Knee Osteoarthritis, this trial is completed. The trial is conducted by Maurizio Fava, MD and has accumulated 18 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Mar 2022 · 4 months · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Mar 2023 · 6 months · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~Jul 2023 · 3 months · monthly snapshot~Jul 2023 – ~Dec 2023 · 5 months · monthly snapshot~Dec 2023 – ~Feb 2024 · 2 months · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Sep 2025 · 11 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – present · 9 months · monthly snapshot

Change History

18 versions recorded
  1. Dec 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2025 — Dec 2025 [monthly]

    Completed PHASE2

  3. Oct 2024 — Sep 2025 [monthly]

    Completed PHASE2

  4. Sep 2024 — Oct 2024 [monthly]

    Completed PHASE2

  5. Aug 2024 — Sep 2024 [monthly]

    Completed PHASE2

Show 13 earlier versions
  1. Jul 2024 — Aug 2024 [monthly]

    Completed PHASE2

    Status: Active Not RecruitingCompleted

  2. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Feb 2024 — Mar 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: RecruitingActive Not Recruiting

  4. Dec 2023 — Feb 2024 [monthly]

    Recruiting PHASE2

  5. Jul 2023 — Dec 2023 [monthly]

    Recruiting PHASE2

  6. Apr 2023 — Jul 2023 [monthly]

    Recruiting PHASE2

  7. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE2

  8. Sep 2022 — Mar 2023 [monthly]

    Recruiting PHASE2

  9. Apr 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  10. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE2

  11. Nov 2021 — Mar 2022 [monthly]

    Recruiting PHASE2

    Status: Not Yet RecruitingRecruiting

  12. Oct 2021 — Nov 2021 [monthly]

    Not Yet Recruiting PHASE2

  13. Sep 2021 — Oct 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Maurizio Fava, MD
Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .